Last week the company disclosed that enrollment into its Phase 3 PD trial for buntanetap was going well and based on the pace of this effort, an interim data analysis from this study should be out sometime in the second quarter of this year. This obviously could be a key near term milestone on the horizon.
Annovis Bio: Moving Forward Against Parki... - Cure Parkinson's
Annovis Bio: Moving Forward Against Parkinson's
Written by
Farooqji
To view profiles and participate in discussions please or .
4 Replies
•
Could this mean a cure
I really really hope the Phase 3 results are positive and the drug is safe. If so, I hope this leads to accelerated approval of this drug.
I wonder why higher dose lesser effect, at 80mg almost no effect. And the results only 25 days, does that higher dose OR longer period the effect will be gone? Hopefully not.
Not what you're looking for?
You may also like...
Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study
https://www.prnewswire.com/news-releases/annovis-bio-announces-two-presentations-at-the-adpd-2023-in
Annovis Bio Buntanetap
With the Buntanetap phase III trial dosing ending soon, I noticed that Annovis Bio stock is dropping
“Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence”
https://www.statnews.com/2024/02/23/annovis-bio-parkinsons-disease-buntanetap/
Anxious to hear any updates from Annovis Bio Butanetap phase 3 trial cohorts
any of the Annovis Bio cohorts have had any updates from his/her experience in this trial they could